Extended Medicare Support for Biosimilar Drugs
This bill aims to extend special payment increases for biosimilar biological products under the Medicare program until 2032. This means Medicare beneficiaries may continue to have access to these medications for a longer period, potentially impacting their treatment costs and access to modern therapies.
Key points
Extends payment increases for biosimilar products in Medicare from 2027 to 2032.
Potential impact on drug accessibility and costs for Medicare beneficiaries.
Expired
Citizen Poll